These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 15003901)

  • 1. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
    Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
    Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
    [No Abstract]   [Full Text] [Related]  

  • 2. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 3. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
    Pitini V; Arrigo C; Altavilla G; Naro C; Righi M
    Leuk Res; 2007 May; 31(5):725-6. PubMed ID: 16978696
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib-responsive hypereosinophilic syndrome.
    Robyn J
    Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
    [No Abstract]   [Full Text] [Related]  

  • 6. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
    von Bubnoff N; Gorantla SP; Thöne S; Peschel C; Duyster J
    Blood; 2006 Jun; 107(12):4970-1; author reply 4972. PubMed ID: 16754777
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ; Tan DC; Yiu RC; How GF
    Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

  • 9. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
    Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A
    Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 11. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
    Wolf D; Gastl G; Rumpold H
    Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
    Breccia M; Cilloni D; Cannella L; Stefanizzi C; Tafuri A; Fama A; Santopietro M; Saglio G; Alimena G
    Cancer Chemother Pharmacol; 2009 May; 63(6):1161-3. PubMed ID: 18989670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
    Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
    Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
    McPherson T; Cowen EW; McBurney E; Klion AD
    Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
    Cools J
    Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
    Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
    Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
    [No Abstract]   [Full Text] [Related]  

  • 20. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.